The global gabapentin market size is expected to reach USD 3,768.43 million by 2034, according to a new study by Polaris Market Research. The report “Gabapentin Market Size, Share, Trends, Industry Analysis Report: By Dosage (Capsule and Tablet), Type, Method, Application, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Gabapentin is a prescription medication used to manage neuropathic pain, epilepsy, and restless legs syndrome by altering nerve signaling in the brain.
The gabapentin market is experiencing steady growth, driven by the increasing prevalence of neuropathic disorders, rising demand for cost-effective generic alternatives, and expanding applications beyond its approved indications. Opportunities in the market include the expansion of distribution channels, particularly through online and retail pharmacies, and the development of improved formulations for enhanced patient compliance.
Key gabapentin market trends include regulatory scrutiny due to potential misuse, growing off-label prescriptions, and strategic collaborations among pharmaceutical companies to strengthen market presence. Overall, the market is expected to expand as awareness of neuropathic conditions increases and demand for affordable treatment options rises.
Gabapentin Market Report Highlights
By dosage, the capsule segment held the largest market share due to their widespread prescription and patient preference for ease of administration. The tablet segment is witnessing notable growth as manufacturers introduce cost-effective generic alternatives.
Based on type, the generic segment held the largest share of the gabapentin market in 2024, led by formulations that offer a cost-effective alternative to branded versions.
In 2024, North America held the largest market share due to high prescription rates and established pharmaceutical infrastructure.
Asia Pacific is witnessing rapid growth, driven by expanding healthcare access and rising demand for cost-effective generic medications.
The gabapentin market features several key players actively involved in the development, manufacturing, and distribution of gabapentin formulations. A few players are Amneal Pharmaceuticals, Inc.; Apotex Inc.; Aurobindo Pharma Ltd.; Dr. Reddy's Laboratories Ltd.; Glenmark Pharmaceuticals Ltd.; Lupin Limited; Mylan N.V.; Pfizer Inc.; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.; and Torrent Pharmaceuticals Ltd.
Polaris Market Research has segmented the gabapentin market report on the basis of dosage, type, method, application, distribution channel, and region:
By Dosage Outlook (Revenue – USD Million, 2020–2034)
Capsule
Tablet
By Type Outlook (Revenue – USD Million, 2020–2034)
Branded
Generic
By Method Outlook (Revenue – USD Million, 2020–2034)
Column-Based
Magnetic Beads
Reagent-Based
Others
By Application Outlook (Revenue – USD Million, 2020–2034)
Neuropathic Pain
Epilepsy
Restless Legs Syndrome
Others
By Distribution Channel Outlook (Revenue – USD Million, 2020–2034)
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
By Regional Outlook (Revenue – USD Million, 2020–2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook